FemTech Mag Editors

FemTech founders face visa barriers that other entrepreneurs don't.

AI chatbots are reshaping how women discover femtech apps based on medical credibility.

Dysmenorrhea, adenomyosis, and fibroids remain vastly understudied despite affecting millions.

Forgotten in research, women fought back to reshape their own medical care.

Three landmark studies finally gave doctors real data on postmenopausal women's health.

The NIH task force offers 15 policy fixes for the drug research gap affecting pregnant patients.

FemTech spans tracking apps, devices, and diagnostics across reproductive stages.

Health systems are buying femtech to plug decades-old gaps in women's care delivery.

FemTech funding concentrates in three categories and seven investors who matter most.

Femtech founders win funding by naming the clinical gap and addressing investor hesitations upfront.

Private funding surges while basic science remains chronically underfunded.

Sensor-equipped apps and AI are helping women get real feedback on pelvic floor exercises.

Period tracking apps sell intimate health data with minimal legal protection or user consent.

Decades of excluding women from trials left femtech regulators with inadequate evidence.

Decades of medical neglect drive millions of women toward tech solutions instead of doctors.

Female founders in women's health receive half the capital but deliver double the returns.

Doctors need rigorous evidence, not brand awareness, to trust women's health technology.

Singular focus on solving one problem leaves users with nowhere to go once it's solved.

Tech platforms censor women's health ads while approving male equivalents.

Millennial women earn more but face worse health outcomes than their mothers did.

Women trust doctors over social media, so clinical credibility must lead your marketing funnel.

FDA rules on device classification and labeling set strict limits on what companies can claim.

Winning women's mental health requires earning trust before offering solutions.

Billions in fines hinge on understanding four overlapping rulebooks most marketers treat as one.

Unified patient acquisition beats fragmented marketing in a consolidator-dominated market.

Women's heart attacks kill twice as fast, yet research still treats them as the exception.

Patients wait nearly a decade for endometriosis diagnosis due to missing diagnostic tools.

Women remain significantly underenrolled in clinical trials, leaving drugs dosed for male bodies.

Maternal health market estimates vary wildly depending on what you're actually counting.

NIH funding for women's health research lags disease burden by staggering margins.

Venture capital finally catches up to decades of neglected women's health research gaps.

Federal funding for women's health research has dropped sharply despite a larger overall budget.

Hospitals cut marketing budgets while demanding proof that spending actually converts patients.

A $600 billion market is reshaping how brands reach women through telehealth, influencers, and AI.

Women's health clinics command patient demand but lag in digital visibility—here's where to start.

How FemTech brands navigate FDA rules, algorithmic suppression, and deep mistrust.

Femtech founders should choose programs by stage, vertical fit, and actual investor access.

Mastering "intended use" and the three FDA pathways can cut years off your regulatory timeline.

Investors now demand clinical data and regulatory clarity even at the seed stage.

Britain's femtech market has tripled in a decade, making it second only to the US globally.

When ad platforms censor anatomy, FemTech brands build owned channels instead.

The two FemTech models split on who pays, reshaping everything from sales to survival.

The sector raised $724 million last year; here's which companies have the budget to actually hire.

A funding boom has created clear winners, but the capital era that built them is ending.

Navigating FDA and FTC rules keeps women's health brands in legal crosshairs.

Life stage and use-case intent, not age alone, determine how to reach reproductive health app users.

Demographic data alone misses why women actually buy wellness products.

Forget age bands—segment women's health audiences by the clinical question they're asking.

FemTech campaigns fail when they skip product-to-audience mapping before the first brief is written.